Medicines Co. (MDCO) Tops Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
The Medicines Company (MDCO) PT Bumped to $31 at Piper Jaffray, Remains Cautious
November 4, 2015 8:59 AM ESTPiper Jaffray analyst David Amsellem reiterated a Neutral rating and boosted his price target on The Medicines Company (NASDAQ: MDCO) to $31.00 (from $28.00) post Q2. The analyst noted a slow update for new launches and long road ahead for PCSK9 keeps them cautious.
commented, "The... More
Chardan Capital Markets Starts The Medicines Company (MDCO) at Buy
November 4, 2015 7:17 AM ESTChardan Capital Markets initiated coverage on The Medicines Company (NASDAQ: MDCO) with a Buy rating and a price target of $50.00.
For an analyst ratings summary and ratings history on The Medicines Company... More
